Nycomed and Affitech extend research deal:
This article was originally published in Clinica
Nycomed Amersham Imaging and Norwegian company Affitech have signed a research agreement for the discovery of fully human antibodies for diagnostic use. This extends a 1999 collaboration deal. Oslo-based Affitech will combine its proprietary antibody library technology and its automated affinity maturation process to generate human antibodies against targets provided by Nycomed. Affitech has rights to milestone and royalty payments from any products incorporating its technology.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.